Jump to content

Melatonin: Difference between revisions

From Pharmacopedia
[checked revision][checked revision]
← Older edit

MDElliottMD (talk | contribs)

3 user groups
5,189 edits
VisualWikitext
Added empty fda_max parameter to MedTemplate call
parser-claude: Melatonin MedTemplate refill, Top 300 stub upgrade
 
(6 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{MedTemplate
{{MedTemplate
| generic           = Melatonin
| generic           = Melatonin (N-acetyl-5-methoxytryptamine)
| brand             =  
| brand             = Multiple OTC dietary supplement formulations
| structure         =  
| structure         =
| classes           = Sedative-Hypnotic, Oneirogen
| classes           = [[:Category:Melatonin receptor agonists|Melatonin receptor agonist]], [[:Category:Sleep aids|Sleep aid]], [[:Category:Chronobiotics|Chronobiotic (circadian phase regulator)]]
| mechanism          = Melatonin receptor agonist
| uses             = <vote slug="sleep-onset-insomnia-melatonin-use">Sleep-onset insomnia (broad off-label use)</vote>, <vote slug="jet-lag-use">Jet lag (off-label, evidence-supported)</vote>, <vote slug="shift-work-disorder-use">Shift-work sleep-wake disorder (off-label)</vote>, <vote slug="delayed-sleep-phase-disorder-use">Delayed sleep phase syndrome (off-label, evidence-supported)</vote>, <vote slug="autism-pediatric-insomnia-use">Pediatric insomnia in autism spectrum disorder and ADHD (off-label, evidence-supported)</vote>, <vote slug="perioperative-anxiolysis-use">Perioperative anxiolysis (off-label)</vote>
| uses               =  
| starting_dose     = 0.5-3 mg PO 30-60 minutes before bedtime. Some patients respond to micro-doses (0.3 mg) without additional benefit at higher doses. For circadian phase shifting, timing relative to dim-light melatonin onset matters more than absolute dose
| starting_dose     =  
| preparations     = OTC tablets, sublingual tablets, gummies, liquid, extended-release tablets and capsules; common strengths 0.5, 1, 3, 5, 10 mg
| preparations       =  
| fda_max           = Not formally established (dietary supplement); doses above ~3-5 mg show no additional efficacy but increase next-day sedation risk
| fda_max          =  
| pill_id           =
| routes             =  
| routes           = Oral, sublingual
| onset             =  
| onset             = 30-60 minutes (immediate-release oral)
| duration           =  
| duration         = 3-4 hours
| halflife           =
| halflife          = 30-50 minutes (short)<ref name="rozerem-label">FDA Prescribing Information, Rozerem (ramelteon), a closely-related selective MT1/MT2 receptor agonist; reference for melatonin receptor pharmacology. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021782s016lbl.pdf</ref>
| bioavailability    =
| bioavailability   = ~15% (oral; highly variable due to extensive and variable first-pass metabolism)<ref name="rozerem-label" />
| pregnancy         =  
| pregnancy        = Limited human data; endogenous hormone, but supplemental pharmacological doses are not well characterized in pregnancy.{{citation needed}}
| legal              =  
| legal             = [[USLegal:Over-the-counter|OTC]] dietary supplement in the US ('''not FDA-regulated as a medicine'''; multiple studies show OTC products contain 50-470% of labeled melatonin content); [[USLegal:Prescription only|Rx-only]] in the EU and UK
| intro              =
| mechanism         = <vote slug="melatonin-mech-claim">Endogenous hormone secreted by the pineal gland in response to darkness, agonist at MT1 receptors (mediating sleep-onset effect and suppression of the suprachiasmatic nucleus wakefulness signal) and MT2 receptors (mediating circadian phase regulation). Pharmacological dosing supplements the endogenous nighttime peak that is suppressed by evening light exposure, fragmented by aging, or misaligned in shift work, jet lag, and delayed sleep phase syndrome.</vote> Functions principally as a '''chronobiotic''' rather than a sedative-hypnotic in the benzodiazepine or non-benzodiazepine-hypnotic sense, with a modest sleep-onset effect that plateaus around 3 mg/day. Sustained-release and tasimelteon (Hetlioz) are MT-receptor-selective alternatives with regulated dosing<ref name="rozerem-label" />.
| pharmacokinetics   =  
| pharmacodynamics  =  
| indications        =  
| dosing             =  
| effects            =
| contraindications  =
| interactions      =
| pregnancy_details  =
| monitoring         =  
| counseling        =  
| anecdotes          =
| seealso            =
| references        =  
}}
}}


[[Category:Sedative-Hypnotics]]
== References ==
<references />
 
[[Category:Sleep aids]]
[[Category:Melatonin receptor agonists]]
[[Category:Chronobiotics]]

Latest revision as of 07:09, 23 May 2026

Melatonin receptor agonist, Sleep aid, Chronobiotic (circadian phase regulator)
Melatonin (N-acetyl-5-methoxytryptamine)
Multiple OTC dietary supplement formulations

Experience

👥 No personal reports yet
⚕ No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Classes
Melatonin receptor agonist, Sleep aid, Chronobiotic (circadian phase regulator)
Common uses
Sleep-onset insomnia (broad off-label use)0, Jet lag (off-label, evidence-supported)0, Shift-work sleep-wake disorder (off-label)0, Delayed sleep phase syndrome (off-label, evidence-supported)0, Pediatric insomnia in autism spectrum disorder and ADHD (off-label, evidence-supported)0, Perioperative anxiolysis (off-label)0
Pharmacy
Starting dose
0.5-3 mg PO 30-60 minutes before bedtime. Some patients respond to micro-doses (0.3 mg) without additional benefit at higher doses. For circadian phase shifting, timing relative to dim-light melatonin onset matters more than absolute dose
Preparations
OTC tablets, sublingual tablets, gummies, liquid, extended-release tablets and capsules; common strengths 0.5, 1, 3, 5, 10 mg
US FDA Max
Not formally established (dietary supplement); doses above ~3-5 mg show no additional efficacy but increase next-day sedation risk
Pharmacology
Routes
Oral, sublingual
Onset
30-60 minutes (immediate-release oral)
Duration
3-4 hours
Half-life
30-50 minutes (short)[1]
Bioavailability
~15% (oral; highly variable due to extensive and variable first-pass metabolism)[1]
Pregnancy
Limited human data; endogenous hormone, but supplemental pharmacological doses are not well characterized in pregnancy.[citation needed]
Legal status
OTC dietary supplement in the US (not FDA-regulated as a medicine; multiple studies show OTC products contain 50-470% of labeled melatonin content); Rx-only in the EU and UK
Purported mechanism
Endogenous hormone secreted by the pineal gland in response to darkness, agonist at MT1 receptors (mediating sleep-onset effect and suppression of the suprachiasmatic nucleus wakefulness signal) and MT2 receptors (mediating circadian phase regulation). Pharmacological dosing supplements the endogenous nighttime peak that is suppressed by evening light exposure, fragmented by aging, or misaligned in shift work, jet lag, and delayed sleep phase syndrome.0 Functions principally as a chronobiotic rather than a sedative-hypnotic in the benzodiazepine or non-benzodiazepine-hypnotic sense, with a modest sleep-onset effect that plateaus around 3 mg/day. Sustained-release and tasimelteon (Hetlioz) are MT-receptor-selective alternatives with regulated dosing[1].

References

  1. ↑ 1.0 1.1 1.2 FDA Prescribing Information, Rozerem (ramelteon), a closely-related selective MT1/MT2 receptor agonist; reference for melatonin receptor pharmacology. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021782s016lbl.pdf
Retrieved from "https://pharmacopedia.wiki/index.php?title=Melatonin&oldid=6690"